drugset / Trial / NCT02194686

Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease

NCT02194686

RandomizedParallel-groupQuadruple-blindTreatment

Summary

1. The number and function of circulating endothelial progenitor cells (EPCs) are inversely associated with coronary risk factors and atherosclerotic diseases. 2. This double-blind, randomized, placebo-controlled trial to evaluate the effects of cilostazol on human early EPCs and endothelial function as well as the potential mechanisms of action in patients with high risk for cardiovascular disease.

Timeline

Start
2013-01
Primary completion
2014-03
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cilostazol Small molecule 100 mg